CLAIMS

1. A topical formulation comprising: a nanoparticle composition comprising a population of particles, wherein the majority of particles have diameters between approximately 10 and approximately 300 nanometers,

wherein the nanoparticle composition comprises at least one aqueous dispersion medium, at least one oil, and at least one surfactant,

wherein the oil is a medium chain triglyceride,

wherein the surfactant is a polysorbate, and

wherein the ratio of oil to surfactant is between about 0.5:1 to about 1:1; and,

wherein the topical formulation further comprises one or more excipients selected from the group consisting of: emulsifying wax, isopropyl myristate, mineral oil, white petrolatum, gelatin, methylparaben, propylparaben, or any combinations thereof,

wherein the topical formulation has a degree of transdermal penetration higher than when said one or more excipients is absent.

2. The topical formulation of claim 1, wherein the topical formulation further comprises emulsifying wax, isopropyl myristate, mineral oil, white petrolatum and gelatin.

3. The topical formulation of claim 1, wherein the topical formulation does not contain parabens.

4. The topical formulation of claim 1, wherein the medium chain triglyceride is an acid containing 6-12 carbons atoms or is Labracfac Lipophile WL 1349 oil.

5. The topical formulation of claim 1, wherein the polysorbate is polysorbate 80.

6. The topical formulation of claim 1, further comprising a known therapeutic agent or independently active biologically active agent, optionally wherein the known therapeutic agent or independently active biologically active agent is a protein, a protein complex, an antibody or botulinum toxin.

14. The formulation of claim 7, formulated as

(i) a deodorant, an antiperspirant, a sunscreen, a shampoo, a conditioner, or any combination thereof, or

(ii) into a cream, a gel, a liniment, a lotion, an ointment, a powder, drops, an oil, a foam, a spray, a patch, a liquid or thickening lotion, or

(iii) as a cosmetic formulation selected from the group consisting of:

skin softeners, nutritional lotion type emulsions, cleansing lotions, cleansing creams, skin milks, emollient lotions, massage creams, emollient creams, make-up bases, lipsticks, facial packs, facial gels, shampoos, rinses, conditioners, body cleansers, hair-tonics, soaps, and any combination thereof.

15. Use of the topical formulation of any one of claims 1-14, in the manufacture of a medicament

(i) for treatment of

a) a condition or disorder associated with sebaceous glands;

b) a condition or disorder associated with sweat glands;

c) a condition or disorder associated with hair follicles;

d) the outer layer of skin; or

any combination thereof, or

(ii) for treatment of a condition or disorder selected from the group consisting of acne, hyperhidrosis, unwanted sweating, bromhidrosis, body odor, chromhidrosis, excess sebum-producing disorders, seborrhea, seborrheic dermatitis, rosacea, hair loss, psoriasis, dermal infections, viral infection, bacterial infection, fungal infection, actinic keratosis, eczematous dermatitis, atopic dermatitis, burns, Raynaud's phenomenon, lupus erthythematosus, hyperpigmentation disorders, melasma, hypopigmentation disorders, vitiligo, skin cancer, squamous cell skin carcinoma, basal cell skin carcinoma, arthritis, osteoarthritis, bruxism, cervical neck pain, dry eyes, gastrointestinal disorders, achalasia, esophageal spasm, gastroparesis, spasm of the sphincter of oddi, anal fissure, anismus, lateral epicondylitis, back pain, lower back pain, upper back pain, masseter muscle hypertrophy, facial nerve disorders~~, facial wrinkles, wrinkles involving the forehead, glabellar, rhytids and/or periorbital regions, unsightly facial expressions, neck lines, hyperfunctional facial lines, hyperkinetic facial lines,~~

~~platysma bands~~, neuromuscular disorders and conditions involving muscular spasm or contracture, facial palsy such as hemi facial spasm, cerebral palsy, spasticisty due to stroke, blepharospasm, facial contracture, dystonia, cervical dystonia, laryngeal dystonia, oromandibular dystonia, writer's cramp, neuralgias, trigeminal neuralgia, neuropathic pain, Parkinson's disease, plantar fasciitis pain, prostate hyperplasia, headache, migraine, essential headache, cervicogenic headache, tension headache, prostatic disorders, prostatic pain, prostatic hypertrophy, restless leg syndrome, rhinitis, allergic rhinitis, sialorrhea, skin pruritis, strabismus, temporomandibular joint ("TMJ") syndrome, tics, Tourette's syndrome, hemifacial spasm, tremor, essential tremor, urinary bladder dysfunction, detrusor sphincter dysnergia, painful bladder, bladder spasticity, overactive bladder, vaginismus, spasticity such as that resulting from multiple sclerosis, retroorbital muscle, various ophthalmologic conditions, and/or combinations thereof, wherein said medicament is to be administered to the skin of a subject,

wherein the topical formulation optionally comprises a known therapeutic agent or independently active biologically active agent.

16. A method for manufacturing a topical formulation, the method comprising steps of:

i) providing:

(a) a premix comprising: an aqueous dispersion medium, an oil, surfactant and optionally a known therapeutic or independently active agent;

(b) a cream or lotion formulation comprising one or more excipients selected from the group consisting of: mineral oil, isopropyl myristate, white petrolatum, emulsifying wax, methyparaben and propylparaben; and,

(c) providing a saline solution;

ii) combining the (a), (b) and (c) to generate the topical formulation of any one of claims 1-14, optionally wherein the premix (a) further comprises propylparaben, methylparaben or combination thereof, and/or wherein the cream or lotion formulation (b) comprises two phases admixed with one another, wherein the first phase comprises methylparaben, optionally wherein the second phase comprises mineral oil, isopropyl myristate, white petrolatum, emulsifying wax, and propylparaben, and/or wherein the saline solution further comprises a paraben.

17. Use of the topical formulation of any one of claims 1-14 for treating a cosmetic condition selected from the group consisting of facial wrinkles, wrinkles involving the forehead, glabellar, rhytids and/or periorbital regions, unsightly facial expressions, neck lines, hyperfunctional facial lines, hyperkinetic facial lines, and platysma bands.